Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EPS (Weighted Average and Diluted): 2023-2025

Historic EPS (Weighted Average and Diluted) for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$0.65.

  • Immunome's EPS (Weighted Average and Diluted) rose 16.67% to -$0.65 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.95, marking a year-over-year increase of 63.63%. This contributed to the annual value of -$5 for FY2024, which is 7.06% up from last year.
  • According to the latest figures from Q3 2025, Immunome's EPS (Weighted Average and Diluted) is -$0.65, which was down 30.00% from -$0.50 recorded in Q2 2025.
  • Immunome's 5-year EPS (Weighted Average and Diluted) high stood at -$0.35 for Q1 2023, and its period low was -$4.22 during Q4 2023.
  • For the 3-year period, Immunome's EPS (Weighted Average and Diluted) averaged around -$1.11, with its median value being -$0.60 (2024).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 617.14% in 2024, then skyrocketed by 79.28% in 2025.
  • Immunome's EPS (Weighted Average and Diluted) (Quarterly) stood at -$4.22 in 2023, then surged by 69.67% to -$1.28 in 2024, then grew by 16.67% to -$0.65 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.65 in Q3 2025, compared to -$0.50 in Q2 2025 and -$0.52 in Q1 2025.